On March 1, according to industry sources,RocheRoche's Roche antibiotic team received a layoff notice and asked to leave at the end of March 31, according to employees.

As for the reasons for the layoffs, it is reported that Rochefen's sales representatives did not meet sales expectations, and due to the impact of the epidemic, there was a significant reduction in the number of pediatric patients and the use of antibiotics.

It is understood that the compensation policy given by Roche is that the coefficient of N times N is the average salary of the last 12 months, and 3 is the basic salary of compensation. Roche also provides internal competitive solutions for employees who do not want to leave.

The data show that Roche's Rocephin is a long-acting and broad-spectrum third-generation cephalosporin antibiotics, which is more active against Gram-negative bacteria and more stable than the first and second generation cephalosporins. Compared with other third-generation cephalosporins, it has the advantages of long half-life, strong tissue penetration and low side effects. it is generally used to treat meningitis, abdominal infection, bone and joint infection, skin and soft tissue infection, reproductive infection including gonorrhea, kidney and urinary tract infection and preoperative infection caused by sensitive bacteria.

Rochfen was listed in Switzerland in 1982, was approved by FDA in 1984, and the original research patent expired in 1996. After the patent expired in 1996, many pharmaceutical companies in China imitated ceftriaxone sodium. Ceftriaxone sodium is not only one of more than 20 kinds of cephalosporin antibiotics approved by the state, but also a variety of national medical insurance category An and national essential drugs catalogue.

Today (March 2)Jincheng MedicineAccording to the announcement, the subsidiary ceftriaxone sodium for injection passed the evaluation of the consistency of the quality and efficacy of generic drugs. So far, the drug has been overrated by four enterprises, including Jincheng Pharmaceutical, and the other three are Qilu Pharmaceutical andKaren Pharmaceutical Co., Ltd., Shandong Runze. And the data show that among the applications for injection overevaluation, the number of ceftriaxone sodium for injection is the largest, with 57 acceptance numbers.

At present, the fifth batch of volume procurement is coming, and the over-rating of ceftriaxone sodium is fully in line with the collection requirements. Under the influence of a series of policies, Roche can also understand if the product sales team is abolished.

Another industry analyst said that Roche's layoffs do not know whether it will sell Roche this product distribution rights, and the transfer of the company is also suspected to be Yiteng Pharmaceutical. Because as early as March 2018, Roche Pharmaceutical (China) officially granted Yiteng Medicine the right to promote and distribute its recombinant human erythropoietin (trade name: Rockman ®) in Chinese mainland. The two companies already have a basis for cooperation.

Earlier, Eli Lilly and Co China announced that it had reached an exclusive agreement with Chinese pharmaceutical company Yiteng Pharmaceuticals to formally grant the product rights and related assets of its antibiotic "Xilu" and "stable credible" products in Chinese mainland from the end of October 2019. If Roche's Rosefin can be won this time, the layout of Yiteng Medicine in antimicrobials will be expanded again. At present, Roche has not responded to the news and we will continue to pay attention.

At the beginning of 2021, the news of layoffs and product line optimization and adjustment of pharmaceutical companies occurred one after another. There is also a revelation today that the first three parties are laying off staff a few days ago, which involves anti-infective and respiratory analgesia product lines. At present, the objects to be cut are concentrated in areas outside the north, Shanghai and Guangzhou, which are mainly representatives of low output value and short years.

It is reported that the compensation scheme for this layoff is as follows: less than one year on the job-Number3; one year on the job-Number5 (the amount of compensation is: N* average monthly salary last year + 3gamma 5* base salary).

In addition to layoffs, the first and third Communist Party will implement major policies such as structural adjustment in the near future. It is understood that the company plans to combine cardiovascular, anti-infective and respiratory analgesia lines, but the specific merger schedule has not yet been announced.

According to analysis, the reasons for the major internal adjustment of the company are as follows: the company's respiratory analgesia line Lexong tablets and anti-infective product line colbital tablets have entered the fourth batch of national collection.

From the perspective of domestic policy direction, drug price reduction is the trend of the times. With volume procurement will also further radiate the country, the formation of price linkage. Due to the emergence of generic drugs, the profitability of generic drugs is already lower than that of new drugs. In the future, the market share of generic drugs through consistency evaluation will increase rapidly and speed up the replacement of imported original research drugs, which will also have an impact on multinational pharmaceutical companies.

In addition to the merger of the product line, the first three announced at the board meeting on February 26th that they had adopted a resolution to transfer the production and sales rights of the company's 11 mature medicines in Japan, including the antihypertensive drug Acecol and the antibacterial drug Banan, to Alfresa Pharmaceuticals, a subsidiary of Alfresa.

According to the resolution, of the 11 mature drugs, 6 products will be transferred to Alfresa Pharmaceuticals in the form of company split, effective from December 1, 2021, and other products will be transferred separately to Alfresa Pharmaceuticals from December 2, 2021. After the split is completed, the first three will receive a total payment of about 3.7 billion yen from Alfresa Pharmaceuticals.

The first three said that in the future, while optimizing the business, the company's resources will be more concentrated in the field of oncology. In line with this policy, the first three communists were poached almost at the same time.GileadKen Takeshita, of the cell therapy business, has been appointed head of global R & D and interim head of clinical research in the first third Communist Party, which will take effect on April 1.

At present, it seems to be an industry trend for multinational pharmaceutical companies to spin off their mature products and focus on the field of high-value diseases. There have been before.Pfizer IncAfter the spin-off of Pfizer Inc Puqiang, its generic brand and generics business unit, and Mailan's merger to form Viatris, Pfizer Inc successfully turned his attention to the biopharmaceutical business. In addition,MerckThe division of basic health care and women's health has also set up a new company, Organon.